TheStreet's Jim Cramer sees Amgen (AMGN) stock as being very cheap after a U.S. court blocked Regeneron (REGN) and Sanofi (SNY) from selling anti-cholesterol drug Praluent. Despite the court's decision, Cramer says Regeneron is also a buy.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.